{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:20:15Z","timestamp":1784164815897,"version":"3.55.0"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2016,1,22]],"date-time":"2016-01-22T00:00:00Z","timestamp":1453420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0146551","type":"journal-article","created":{"date-parts":[[2016,1,22]],"date-time":"2016-01-22T21:03:07Z","timestamp":1453496587000},"page":"e0146551","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Comparative Cost-Effectiveness of Drugs in Early versus Late Stages of Cancer; Review of the Literature and a Case Study in Breast Cancer"],"prefix":"10.1371","volume":"11","author":[{"given":"Evgeni","family":"Dvortsin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Gout-Zwart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst-Lodewijk Marie","family":"Eijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"van Brussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,1,22]]},"reference":[{"key":"ref1","unstructured":"Zorginstituutnederland.nl [Internet]. Dutch Health Care Institute; Accessed 9 Jul 2015. Available: http:\/\/www.zorginstituutnederland.nl<\/ext-link>."},{"key":"ref2","unstructured":"Nice.org.uk [Internet]. English Health Care Authority; Accessed 9 Jul 2015. Available: http:\/\/www.nice.org.uk\/guidance\/qs13<\/ext-link>"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.healthpol.2010.02.005","article-title":"Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers","volume":"96","author":"JJ Carlsonn","year":"2010","journal-title":"Health Policy"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"c2509","DOI":"10.1136\/bmj.c2509","article-title":"Cost effectiveness of pneumococcal vaccination among Dutch infants; economic analysis of the seven valent pneumococcal vaccine and forecast for the 10 valent and 13 valent vaccines","volume":"340","author":"MH Rozenbaum","year":"2010","journal-title":"BMJ"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10198-013-0459-2","article-title":"Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique","volume":"15","author":"B Parkinson","year":"2014","journal-title":"Eur J Health Econ"},{"issue":"9555","key":"ref6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial","volume":"369","author":"I Smith","year":"2007","journal-title":"Lancet"},{"issue":"19","key":"ref7","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","article-title":"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group","volume":"23","author":"M Marty","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"ref8","first-page":"3","article-title":"Pharmacoeconomics and market access in Europe: case studies in Scotland and The Netherlands","volume":"6","author":"K Tolley","year":"2006","journal-title":"ISPOR Connections"},{"key":"ref9","unstructured":"Scottishmedicines.org.uk [Internet]. Scottish Health Care Authority. Accessed 5 Jan 2015. Available from https:\/\/www.scottishmedicines.org.uk<\/ext-link>."},{"key":"ref10","unstructured":"Scottish Medicines Consortium. Bortezomib 3.5mg powder for solution for injection (Velcade\u00ae<\/sup>) 2013; 927\/13."},{"key":"ref11","unstructured":"Scottish Medicines Consortium. Bortezomib 3.5mg powder for solution for intravenous injection (Velcade\u00ae<\/sup>) 2009; 302\/06."},{"key":"ref12","unstructured":"Zorginstituutnederland.nl [Internet]. Dutch Health Care Institute; Stukken ter kennisneming\/Herbeoordeling en duiding trastuzumab (Herceptin\u00ae<\/sup>); Accessed 9 Jul 2015. Available: https:\/\/www.zorginstituutnederland.nl\/binaries\/content\/documents\/zinl-www\/documenten\/publicaties\/geneesmiddelbeoordelingen\/2014\/1406-trastuzumab-herceptin\/1406-trastuzumab-herceptin\/trastuzumab+-Herceptin-.pdf<\/ext-link>"},{"key":"ref13","unstructured":"Statline.cbs.nl [Internet]. Dutch Bureau for Statistics; Accessed 10 Jan 2015. Available: http:\/\/statline.cbs.nl\/Statweb\/publication\/?DM=SLNL&PA=37360ned&D1=0&D2=l&D3=59-99&D4=61-63&HDR=G1,T&STB=G3,G2&VW=T<\/ext-link>."},{"key":"ref14","unstructured":"Inflation.eu [Internet]. Worldwide inflation data\u2014current and historic inflation by country; Accessed 12 Apr 2015. Available: http:\/\/nl.inflation.eu\/inflatiecijfers\/historische-cpi-inflatie.aspx<\/ext-link>."},{"issue":"16","key":"ref15","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1200\/JCO.2006.08.8005","article-title":"Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab","volume":"25","author":"D Curran","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref16","unstructured":"Scottishmedicines.org.uk [Internet]. Scottish Health Care Authority. Accessed 5 Feb 2015. Available: https:\/\/www.scottishmedicines.org.uk\/files\/cetuximab__Erbitux_279-06.pdf<\/ext-link>."},{"key":"ref17","unstructured":"Zorginstituutnederland.nl [Internet]. Dutch Health Care Institute; Accessed 10 April 2015. Available: http:\/\/www.zorginstituutnederland.nl\/binaries\/content\/documents\/zinl-www\/documenten\/publicaties\/geneesmiddelbeoordelingen\/2007\/0701-cetuximab-erbitux\/0701-cetuximab-erbitux\/cetuximab+%28Erbitux%29.pdf<\/ext-link>."},{"key":"ref18","unstructured":"Zorginstituutnederland.nl [Internet]. Dutch Health Care Institute; Accessed 5 Feb 2015. Available: http:\/\/www.zorginstituutnederland.nl\/binaries\/content\/documents\/zinl-www\/documenten\/publicaties\/geneesmiddelbeoordelingen\/2009\/0910-cetuximab-erbitux\/0910-cetuximab-erbitux\/cetuximab+%28Erbitux%29.pdf<\/ext-link>."},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"JB Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"ref20","unstructured":"Zorginstituutnederland.nl [Internet]. Dutch Health Care Institute; Accessed 10 April 2015. Available: http:\/\/www.zorginstituutnederland.nl\/binaries\/content\/documents\/zinl-www\/documenten\/publicaties\/geneesmiddelbeoordelingen\/2007\/0709-bortezomib-velcade\/0709-bortezomib-velcade\/bortezomib+%28Velcade%29.pdf<\/ext-link>."},{"key":"ref21","unstructured":"Scottish Medicines Consortium. Bosutinib 100mg, 500mg film-coated tablets (Bosulif \u00ae<\/sup>) 2013;910\/13."},{"key":"ref22","unstructured":"Ncbi.nlm.nih.gov [Internet]. US National Library of Medicine\u2014National Institutes of Health; Accessed 5 Jan 2015. Available: http:\/\/www.ncbi.nlm.nih.gov\/pubmed<\/ext-link>."},{"key":"ref23","unstructured":"Nice.org.uk [Internet]. English Health Care Authority; Accessed 5 Feb 2015. Available: https:\/\/www.nice.org.uk\/guidance\/ta129\/chapter\/3-the-manufacturers-submission<\/ext-link>"},{"issue":"5","key":"ref24","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1524-4733.2007.00302.x","article-title":"An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom","volume":"11","author":"B Brown","year":"2008","journal-title":"Value Health"},{"key":"ref25","unstructured":"Nice.org.uk [Internet]. English Health Care Authority; Accessed 6 Feb 2015. Available: http:\/\/www.nice.org.uk\/guidance\/ta145\/chapter\/3-the-manufacturers-submission<\/ext-link>."},{"issue":"6","key":"ref26","doi-asserted-by":"crossref","first-page":"e38557","DOI":"10.1371\/journal.pone.0038557","article-title":"Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer","volume":"7","author":"MB Hannouf","year":"2012","journal-title":"PLoS One"},{"key":"ref27","unstructured":"Nice.org.uk [Internet]. English Health Care Authority; Accessed 6 Feb 2015. Available from https:\/\/www.nice.org.uk\/guidance\/ta172\/chapter\/3-the-manufacturers-submission<\/ext-link>."},{"issue":"6","key":"ref28","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/annonc\/mdi188","article-title":"A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis","volume":"16","author":"J Norum","year":"2005","journal-title":"Ann Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0146551","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T15:45:37Z","timestamp":1589039137000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0146551"}},"subtitle":[],"editor":[{"given":"Daniele","family":"Generali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,1,22]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,1,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0146551","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,22]]}}}